Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England

Jamie Lopez Bernal, Nick Andrews, Charlotte Gower, Julia Stowe, Chris Robertson, Elise Tessier, Ruth Simmons, Simon Cottrell, Richard Roberts, Mark O’Doherty, Kevin Brown, Claire Cameron, Diane Stockton, Jim McMenamin, Mary Ramsay
doi: https://doi.org/10.1101/2021.03.01.21252652

Data Availability

Individual level data is not publically available. Aggregated data on cases and vaccination rates are available via the following links: https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports and https://www.gov.uk/government/publications/covid-19-vaccine-monitoring-reports

Back to top
Posted March 02, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England
Jamie Lopez Bernal, Nick Andrews, Charlotte Gower, Julia Stowe, Chris Robertson, Elise Tessier, Ruth Simmons, Simon Cottrell, Richard Roberts, Mark O’Doherty, Kevin Brown, Claire Cameron, Diane Stockton, Jim McMenamin, Mary Ramsay
medRxiv 2021.03.01.21252652; doi: https://doi.org/10.1101/2021.03.01.21252652
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area